Genentech's Giredestrant Reduced Risk of Invasive Disease Recurrence or Death by 30% in ER-positive Early-Stage Breast Cancer

Core Insights - Genentech, a member of the Roche Group, announced positive data from the Phase III lidERA Breast Cancer study evaluating giredestrant as an adjuvant endocrine treatment for early-stage breast cancer [1] Group 1: Study Results - The interim analysis indicated that adjuvant giredestrant significantly reduced the risk of invasive disease [1]